Identification of predisposition genes for Ewing sarcoma segregating in high-risk pedigrees |
Huntsman Cancer Institute / Lisa Cannon-Albright, PhD |
Innovation Grants |
2012 |
Utah |
V alpha-invariant NKT cells as a novel platform for cancer immunotherapy |
Baylor College of Medicine / Leonid Metelitsa, MD, PhD |
Innovation Grants |
2012 |
Texas |
Developing Immune-modulatory Strategies Against Primary and Metastatic Tumors in the Central Nervous System |
Case Western Reserve University / Alex Huang, MD, PhD |
Innovation Grants |
2012 |
Ohio |
Development of the Next Generation FLT3 Inhibitors for Pediatric AML and Infant ALL |
The Johns Hopkins University School of Medicine / Donald Small, MD, PhD |
Innovation Grants |
2012 |
Maryland |
Modeling Pediatric Leukemia in the Zebrafish to Enable Discovery of New Anti-Leukemic Compounds |
University of California, San Diego / David Traver, MD |
Innovation Grants |
2012 |
California |
A novel mouse model of rhabdomyosarcoma |
Vanderbilt University Medical Center / Chin Chiang, PhD |
Innovation Grants |
2012 |
Tennessee |
Mechanisms of LYL1-associated T-ALL development |
Baylor College of Medicine / Margaret Goodell, PhD |
Innovation Grants |
2012 |
Texas |
Searching for genetic vulnerabilities in osteosarcoma through genome-wide RNAi screening |
Dana-Farber Cancer Institute / Stuart Orkin, MD |
Innovation Grants |
2012 |
Massachusetts |
In-UTR mutations in neuroblastoma: Functional consequences and therapeutic implications |
Children’s Hospital of Philadelphia / Andrei Thomas-Tikhonenko, PhD |
Innovation Grants |
2012 |
Pennsylvania |
Identification and validation of new therapeutic targets in pediatric leukemia through an aneuploidy-based synthetic lethality screen |
Dana-Farber Cancer Institute / David Pellman, MD |
Innovation Grants |
2012 |
Massachusetts |